$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2017 [Report Updated: 31-10-2017]

Published by Global Markets Direct: 31 Oct 2017 | 139756 | In Stock

Introduction

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2017

Summary

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The latest report Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2017, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron- and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively. Report covers products from therapy areas Hematological Disorders, Metabolic Disorders, Dermatology, Gastrointestinal, Oncology, Cardiovascular, Central Nervous System and Musculoskeletal Disorders which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia, Inflammatory Bowel Disease, Wounds, Brain Edema, Brain Injury, Colitis, Congestive Heart Failure (Heart Failure), Diabetes, Diabetic Foot Ulcers, Muscle Injury, Myelodysplastic Syndrome, Obesity and Post-Myocardial Infarction.

Furthermore, this report also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)

- The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects

- The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2017 [Report Updated: 31-10-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development

    Bayer AG

    FibroGen Inc

    GlaxoSmithKline Plc

    Japan Tobacco Inc

    Sigmoid Pharma Ltd

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles

    daprodustat - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    dimethyloxalylglycine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FG-2216 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FG-4497 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FG-6874 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    JTZ-951 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    molidustat - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    roxadustat - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products

    Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones

    Featured News & Press Releases

    Jun 05, 2017: European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

    Mar 31, 2017: FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS

    Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

    Jan 30, 2017: FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China

    Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease

    Oct 31, 2016: FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China

    Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan

    Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering .0 Million Milestone Payment

    Apr 20, 2016: Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis

    Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease

    Nov 03, 2015: FibroGen to Present Roxadustat Clinical Data in Four Presentations at American Society of Nephrology - Kidney Week 2015

    Oct 22, 2015: Phase 2 Data For Investigational Orally Active Hif-Phi Roxadustat Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality

    Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia

    May 07, 2015: Fibrogen Announces Receipt Of Milestone Payment From Astrazeneca For Successful Completion Of Long-Term Pre-Clinical Safety Studies Of Roxadustat

    Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

139756 | GMDHC1068TDB

Number of Pages

58

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembr...
20 Feb 2018 by Global Markets Direct USD $3,500 More Info
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2018
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 o...
31 Jan 2018 by Global Markets Direct USD $3,500 More Info
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor-Mechanism of a...
01 Sep 2017 by Delve Insight USD $1,000 More Info
Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) -Pipeline Insights, 2017
DelveInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)-Mechanism of action Ins...
01 Sep 2017 by Delve Insight USD $1,200 More Info
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Pipeline Review, H2 2017
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembr...
16 Aug 2017 by Global Markets Direct USD $3,500 More Info
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2017
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 o...
25 Jul 2017 by Global Markets Direct USD $3,500 More Info
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitors-Pipeline Insi...
30 May 2017 by Delve Insight USD $1,000 More Info
Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) -Pipeline Insights, 2017
DelveInsight’s, “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)-Pipeline Insights, 2017...
30 May 2017 by Delve Insight USD $1,000 More Info
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H2 2016
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 o...
28 Dec 2016 by Global Markets Direct USD $3,500 More Info
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembr...
26 Oct 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2017 [Report Updated: 31-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data